Jane Street Group LLC Buys Shares of 11,400 ProQR Therapeutics (NASDAQ:PRQR)

Jane Street Group LLC purchased a new stake in shares of ProQR Therapeutics (NASDAQ:PRQR) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 11,400 shares of the biopharmaceutical company’s stock, valued at approximately $30,000.

Other institutional investors also recently modified their holdings of the company. Invesco Ltd. bought a new stake in ProQR Therapeutics during the 4th quarter worth approximately $32,000. Alpine Global Management LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at $39,000. Two Sigma Securities LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at $40,000. ADAR1 Capital Management LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at $54,000. Finally, Jump Financial LLC purchased a new stake in ProQR Therapeutics during the 4th quarter valued at $71,000. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Price Performance

NASDAQ PRQR opened at $1.83 on Tuesday. The company has a market cap of $192.54 million, a P/E ratio of -5.72 and a beta of 0.31. The stock has a 50-day moving average of $1.51 and a two-hundred day moving average of $2.12. ProQR Therapeutics has a 1-year low of $1.07 and a 1-year high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The company had revenue of $4.89 million during the quarter, compared to analysts’ expectations of $4.90 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. On average, analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Evercore ISI started coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an “outperform” rating and a $5.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of ProQR Therapeutics in a report on Tuesday, April 29th. They issued an “overweight” rating and a $8.00 price objective on the stock. Chardan Capital reissued a “buy” rating and issued a $4.00 price objective on shares of ProQR Therapeutics in a report on Friday, March 14th. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a report on Monday, March 10th. Finally, Oppenheimer lowered their target price on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.00.

ProQR Therapeutics Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).